SG11201811543XA - Rotigotine behenate, and manufacturing method and application thereof - Google Patents

Rotigotine behenate, and manufacturing method and application thereof

Info

Publication number
SG11201811543XA
SG11201811543XA SG11201811543XA SG11201811543XA SG11201811543XA SG 11201811543X A SG11201811543X A SG 11201811543XA SG 11201811543X A SG11201811543X A SG 11201811543XA SG 11201811543X A SG11201811543X A SG 11201811543XA SG 11201811543X A SG11201811543X A SG 11201811543XA
Authority
SG
Singapore
Prior art keywords
rotigotine behenate
manufacturing
application
rotigotine
behenate
Prior art date
Application number
SG11201811543XA
Other languages
English (en)
Inventor
Mina Yang
Yongtao Jiang
Ying Meng
Tao Wang
qian qian Xu
Xin Shao
Chunjie Sha
Original Assignee
Shandong luye pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong luye pharmaceutical co ltd filed Critical Shandong luye pharmaceutical co ltd
Publication of SG11201811543XA publication Critical patent/SG11201811543XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10Thiophene
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
SG11201811543XA 2016-07-21 2016-07-21 Rotigotine behenate, and manufacturing method and application thereof SG11201811543XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/090803 WO2018014277A1 (zh) 2016-07-21 2016-07-21 罗替戈汀山嵛酸酯及其制备方法和用途

Publications (1)

Publication Number Publication Date
SG11201811543XA true SG11201811543XA (en) 2019-02-27

Family

ID=60992805

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811543XA SG11201811543XA (en) 2016-07-21 2016-07-21 Rotigotine behenate, and manufacturing method and application thereof

Country Status (15)

Country Link
US (2) US10669249B2 (https=)
EP (1) EP3489227B1 (https=)
JP (1) JP6751208B2 (https=)
KR (1) KR20190031314A (https=)
CN (1) CN109415335B (https=)
AU (1) AU2016415408B2 (https=)
BR (1) BR112019001035A2 (https=)
CA (1) CA3030043C (https=)
ES (1) ES2855976T3 (https=)
MY (1) MY195897A (https=)
PH (1) PH12018550212A1 (https=)
PL (1) PL3489227T3 (https=)
RU (1) RU2717542C9 (https=)
SG (1) SG11201811543XA (https=)
WO (1) WO2018014277A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение
CN108341798B (zh) * 2017-01-23 2021-05-25 沈阳药科大学 罗替戈汀衍生物及其制备和应用
CN114423746A (zh) * 2019-09-30 2022-04-29 山东绿叶制药有限公司 化合物及其制备方法和用途
JP7621009B2 (ja) * 2020-10-27 2025-01-24 ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 テトラヒドロナフタレン系化合物、その医薬組成物及びその使用
WO2024208226A1 (zh) * 2023-04-04 2024-10-10 广州市恒诺康医药科技有限公司 四氢萘类化合物、其药物组合物及其用途
CN119504742B (zh) * 2024-11-18 2025-10-28 陕西师范大学 一种娃儿藤碱和安托芬的全合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
KR101481643B1 (ko) 2010-11-25 2015-01-12 산동 루예 파마슈티칼 컴파니 리미티드 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물
WO2013168033A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9956201B2 (en) * 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение

Also Published As

Publication number Publication date
BR112019001035A2 (pt) 2019-04-30
PL3489227T3 (pl) 2021-05-04
JP2019523297A (ja) 2019-08-22
MY195897A (en) 2023-02-27
US20200255396A1 (en) 2020-08-13
RU2717542C1 (ru) 2020-03-24
PH12018550212A1 (en) 2019-10-28
AU2016415408B2 (en) 2019-04-11
EP3489227B1 (en) 2020-10-21
US10669249B2 (en) 2020-06-02
CN109415335A (zh) 2019-03-01
AU2016415408A1 (en) 2019-01-17
CA3030043C (en) 2021-01-19
JP6751208B2 (ja) 2020-09-02
WO2018014277A1 (zh) 2018-01-25
CN109415335B (zh) 2020-06-05
US20190330177A1 (en) 2019-10-31
EP3489227A4 (en) 2020-01-22
ES2855976T3 (es) 2021-09-27
EP3489227A1 (en) 2019-05-29
US11111227B2 (en) 2021-09-07
RU2717542C9 (ru) 2020-08-12
CA3030043A1 (en) 2018-01-25
KR20190031314A (ko) 2019-03-25

Similar Documents

Publication Publication Date Title
PH12018550212A1 (en) Rotigotine behenate and preparation method and use thereof
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20190181A1 (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX2019006878A (es) Uso de flecainida como un agente anti-conexina y metodo para potenciar los efectos de un farmaco psicotropico.
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
ZA201508750B (en) Compounds of '3-(5-sustituted oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester', process and applications thereof
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
MX2016004967A (es) Tratamiento para cancer pancreatico.
CO2017010018A2 (es) Derivados de ácido (s)-2’-vinil-abscísico
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
CR20170261A (es) Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa
EA201690236A1 (ru) Производные индол-3-карбинола
MX384260B (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
TR201903234T4 (tr) Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.